<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11859365</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.244</article-id><article-id pub-id-type="other">EPP0001</article-id><article-id pub-id-type="pii">S092493382400244X</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Opioid Use Disorder in Three Samples of the Lebanese Population: Correlation with Clinical and Genetic Factors</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chamoun</surname><given-names>K.</given-names></name><xref rid="aff0394" ref-type="aff">
<sup>1</sup></xref><xref rid="aff0395" ref-type="aff">
<sup>2</sup></xref><xref rid="aff0396" ref-type="aff">
<sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hajj Moussa Lteif</surname><given-names>F.</given-names></name><xref rid="aff0394" ref-type="aff">
<sup>1</sup></xref><xref rid="aff0395" ref-type="aff">
<sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Salameh</surname><given-names>P.</given-names></name><xref rid="aff0397" ref-type="aff">
<sup>4</sup></xref><xref rid="aff0398" ref-type="aff">
<sup>5</sup></xref><xref rid="aff0399" ref-type="aff">
<sup>6</sup></xref><xref rid="aff0400" ref-type="aff">
<sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sacre</surname><given-names>H.</given-names></name><xref rid="aff0397" ref-type="aff">
<sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Haddad</surname><given-names>R.</given-names></name><xref rid="aff0401" ref-type="aff">
<sup>8</sup></xref><xref rid="aff0402" ref-type="aff">
<sup>9</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rabbaa</surname><given-names>L.</given-names></name><xref rid="aff0394" ref-type="aff">
<sup>1</sup></xref><xref rid="aff0395" ref-type="aff">
<sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Megarbane</surname><given-names>B.</given-names></name><xref rid="aff0396" ref-type="aff">
<sup>3</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Hajj</surname><given-names>A.</given-names></name><xref rid="aff0394" ref-type="aff">
<sup>1</sup></xref><xref rid="aff0397" ref-type="aff">
<sup>4</sup></xref><xref rid="aff0403" ref-type="aff">
<sup>10</sup></xref><xref rid="aff0404" ref-type="aff">
<sup>11</sup></xref><xref rid="cor0105" ref-type="corresp">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="aff0394">
<sup>1</sup>Laboratoire de Pharmacologie, <institution>Pharmacie Clinique et Contr&#x000f4;le de Qualit&#x000e9; des M&#x000e9;dicaments</institution></aff><aff id="aff0395">
<sup>2</sup>Faculty of Pharmacy, <institution>Saint Joseph University</institution>, <city>Beirut</city>, <country>Lebanon</country></aff><aff id="aff0396">
<sup>3</sup>Inserm, UMR-S1144, <institution>Universit&#x000e9; Paris Cit&#x000e9;</institution>, <city>Paris</city>, <country>France</country></aff><aff id="aff0397">
<sup>4</sup><institution>INSPECT-LB (Institut National de Sant&#x000e9; Publique, d&#x02019;&#x000c9;pid&#x000e9;miologie Clinique et de Toxicologie-Liban)</institution>, <city>Beirut</city></aff><aff id="aff0398">
<sup>5</sup><institution>School of Medicine, Lebanese American University</institution>, <city>Byblos</city>, <country>Lebanon</country></aff><aff id="aff0399">
<sup>6</sup>Department of Primary Care and Population Health, <institution>University of Nicosia Medical School</institution>, <city>Nicosia</city>, <country>Cyprus</country></aff><aff id="aff0400"><sup>7</sup>Faculty of Pharmacy, <institution>Lebanese University</institution>, <city>Hadat</city></aff><aff id="aff0401"><sup>8</sup>Faculty of Medical Sciences, Psychiatry Department, <institution>Lebanese University</institution></aff><aff id="aff0402"><sup>9</sup>Faculty of Medicine, Psychiatry Department, <institution>Saint Joseph University</institution>, <city>Beirut</city>, <country>Lebanon</country></aff><aff id="aff0403"><sup>10</sup>Faculty of Pharmacy, <institution>Universit&#x000e9; Laval</institution></aff><aff id="aff0404"><sup>11</sup>Oncology Division, <institution>CHU de Qu&#x000e9;bec- Universit&#x000e9; Laval Research Center</institution>, <city>Quebec</city>, <country>Canada</country></aff><author-notes><corresp id="cor0105"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="219">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S99</fpage><lpage>S99</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S092493382400244Xa.pdf"/><abstract><sec id="sec0629"><title>Introduction</title><p>Opioid Use Disorder (OUD) is a severe and recurrent condition that contributes to a global prevalence of disabilities. Accumulating evidence suggests a potential convergence of clinical and genetic factors underlying OUD.</p></sec><sec id="sec0630"><title>Objectives</title><p>This study explores the clinical and genetic factors associated with OUD in the Lebanese population.</p></sec><sec id="sec0631"><title>Methods</title><p>A cross-sectional study in the Lebanese population included three different groups of participants stratified according to the cut-off of the revised Opioid Risk Tool (ORT-OUD): (1) Low-risk group for OUD (n=513; general population; ORT-OUD score &#x0003c;2.5); (2) High-risk group for OUD (n=87; general population; ORT-OUD score &#x02265;3); (3) a third group consisting of patients clinically diagnosed with OUD according to the DSM-5 (n=46). The survey included sociodemographic information and used validated scales to assess other substance use disorders, sleep disturbances, depression, and anxiety. Genotyping for the <italic toggle="yes">COMT</italic>, <italic toggle="yes">MTHFR</italic>, and <italic toggle="yes">CRY2</italic> genes was conducted for 91 patients using a real-time PCR (Roche<sup>&#x000ae;</sup>). Bivariate and multivariate analyses were conducted to identify the associations between OUD risk and sociodemographic, clinical, and genetic factors.</p></sec><sec id="sec0632"><title>Results</title><p>This study enrolled 646 participants. Multivariate analysis showed significant associations between risk of developing an OUD and cigarette smoking (B=0.583), worse insomnia scores (B=0.074) and Alcohol, Smoking and Substance Involvement Screening Test-alcohol (B=0.053) scores, male gender (B=13.351), lack of education (B=4.159), unemployment (B=7.235), low income (B=11.285), lack of healthcare coverage (B=4.190), neuropsychiatric disorders (B=7.966). Conversely, OUD risk was negatively correlated with the morning chronotype (B=-0.372). Bivariate analysis showed that the <italic toggle="yes">CRY2</italic> AA genotype was significantly associated with a higher risk of OUD; nevertheless, none of the genetic factors remained significant in the multivariable model.</p></sec><sec id="sec0633"><title>Conclusions</title><p>This study identified several sociodemographic, clinical, and genetic factors that could potentially increase the risk of developing OUD in the Lebanese population. Further research is needed to clarify risk factors and underlying mechanisms, enabling the development of more effective prevention strategies.</p></sec><sec id="sec0634"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>